Recent studies on whether blocking or inhibiting the activation of the NLRP3 inflammasome through a nonsteroidal anti-inflammatory drug (fenamate) may be essential in memory loss protection in a mouse model of Alzheimer's disease have shown encouraging results [12]. The gene discussed is NLRP3; the disease is early-onset autosomal dominant Alzheimer disease.